Press release
Loeb Benson Hires Sun Huateng as Managing Director and Portfolio Manager
Rejoins the firm as Chief Investment Officer—Non-traditional Strategies and Head of Portfolio Management in Hong Kong OfficeHong Kong – Loeb Benson, a pioneer asset manager focused on the capital markets and financial advice while specializing in maximizing clients’ investment profits, has hired Sun Huateng as a Managing Director and Portfolio Manager.
Mr. Huateng will return to the firm in a new role as Chief Investment Officer—Non-traditional Strategies and Head of Portfolio Management in the Hong Kong office, as well as a member of Loeb Benson’s Investment Committee. He will begin next month and will report to Mr. Richard G. Man-tat, Loeb Benson’s Chairman and Chief Executive Officer.
Mr. Huateng, who was a Senior Portfolio Manager at Loeb Benson, will work closely with Mr. Man-tat on the oversight of several non-traditional investment teams. In addition, he will assume generalist portfolio management responsibilities as part of his new role. In his previous role at Loeb Benson, Mr. Huateng was a member of the Loeb Benson Investment Committee and managed a range of portfolios that included Loeb Benson total return separate accounts.
Said Mr. Man-tat “Sun is a talented, highly experienced investor with broad market expertise and a deep knowledge of Loeb Benson, and his return will further enhance our global investment platform.” Mr. Man-tat continued: “Sun will be able to seamlessly contribute to our investment process and efforts on behalf of Loeb Benson’s clients. We are very pleased that he is returning to Loeb Benson in a senior portfolio management role.”
Said Mr. Huateng “I look forward to return to Loeb Benson and become a member of the firm’s portfolio management team, which is one of the deepest in the investment management industry.”
About Loeb Benson
Loeb Benson is focused on the capital markets and financial advisory needs of the financial services industry while specializing in maximizing clients’ investment profits. With expertise in sales and trading, analytics and asset management, Loeb Benson is uniquely qualified to create value for clients in all market conditions, and we are strategically building on a longstanding commitment to offer a broad range of services. Loeb Benson offers comprehensive investment management capabilities that span nearly all segments of the global capital markets. Our investment solutions, tailored to the unique return and risk objectives of clients draw on a robust body of proprietary research and a collaborative culture that encourages independent thought and healthy debate.
Loeb Benson
Address: Wheelock House, 20 Pedder Street, Hong Kong
public@loeb-benson.com
Kevin Edwards
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Loeb Benson Hires Sun Huateng as Managing Director and Portfolio Manager here
News-ID: 1070797 • Views: …
More Releases from Loeb Benson
Loeb Benson Hires Equity Specialists in Growth and Dividend Strategies to Contin …
Hires Lee Tak-hay, Simon Zhenjiang, Yi Xipeng and Chen Xiuguo in Hong Kong
Hong Kong – Loeb Benson, a pioneer asset manager focused on the capital markets and financial advice while specializing in maximizing clients’ investment profits, has hired Lee Tak-hay, Simon Zhenjiang, Yi Xipeng and Chen Xiuguo to join its Asian equities teams as part of its multi-year effort to deepen and expand its equity solutions for investors.
Mr.…
More Releases for Huateng
Huateng Pharma to Exhibit at CPhI Milan 2024
Huateng Pharma, a leading supplier of PEG derivatives and trusted CDMO partner, is thrilled to announce its participation in CPhI Worldwide 2024, scheduled for October 14-16 in Milan, Italy. Attendees are encouraged to visit booth #3F81, where the Huateng team will present its innovative capabilities in GMP-grade PEG derivative production, Contract Development and Manufacturing Organization (CDMO) services, and fine chemicals.
Sonia Lee, Business Development Manager at Huateng Pharma, extends an invitation…
Huateng Pharma Introduces Y-Shape PEG NHS
Changsha, China, July 22, 2024 - Huateng Pharma, a global leader in PEG derivatives and a premier CDMO for APIs and intermediates, is excited to announce the launch of its latest product, Y-Shape PEG NHS. This cutting-edge Succinimidyl Carboxymethyl Ester branched 2ARM PEG offers a revolutionary approach to amine PEGylation, enhancing the modification of proteins and other biologics.
PEGylation, the technique of attaching a PEG derivative to molecules, is crucial for…
Huateng Pharma Launches New Innovative Product: Piroctone Olamine
Huateng Pharma, a leading Contract Development and Manufacturing Organization (CDMO), is proud to announce the launch of its latest product, Piroctone Olamine (CAS: 68890-66-4). This addition underscores Huateng Pharma's commitment to providing high-quality pharmaceutical ingredients to meet the diverse needs of the global health and personal care industries.
Piroctone Olamine is a highly effective antifungal and antimicrobial agent commonly used in personal care products, particularly in dandruff shampoos and other hair…
Huateng Pharma Unveils Cutting-Edge Gastrointestinal API Intermediates
Huateng Pharma, a renowned name in the pharmaceutical industry, is proud to introduce a groundbreaking addition to its product portfolio - Gastrointestinal API Intermediates. This new line features the highly anticipated Fexuprazan Intermediate and Vonoprazan Intermediates, designed to empower pharmaceutical manufacturers with top-tier solutions.
The Fexuprazan Intermediate, boasting the chemical compound Methyl 5-(2,4-Difluorophenyl)-4-methoxypyrrole-3-carboxylate (CAS NO. 1902955-29-6), and the Vonoprazan Intermediates, which include 5-(2-Fluorophenyl)-1H-pyrrole-3-carbaldehyde (CAS NO.: 881674-56-2) and Pyridine-3-sulfonyl chloride (CAS NO.:…
Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. The U.S. Food and Drug Administration (FDA) approved it for flea treatment in dogs under the trade name Bravecto in May 2014 and for topical treatment in cats in November 2019.
Fluralaner is a novel isooxazoline broad-spectrum insecticide that acts on γ-aminobutyric acid (GABA) receptors and has good activity against ticks, fleas,…
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number…